Outset Medical (Nasdaq: OM) shares got a boost today on fourth-quarter results that topped the consensus forecast on Wall ...

During the fourth quarter, Outset Medical made significant progress. Gross margin, essential for profitability, improved dramatically. It reached 37.7%, reflecting operational efficiencies compared to ...

The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological ...

The FDA clearance of the Tablo® Hemodialysis System as a solution for both hospital and home use signifies a significant advancement in dialysis technology, potentially expanding their customer base.

Outset provided 2025 revenue guidance of $115 million to $125 million, and non-GAAP gross margin guidance in the high-30% range. Additionally, the company expects to use less than $50 million of cash ...

The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and ...

The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and ...